Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment

2002, Screening for depression: recommendations and rationale, Ann Intern Med, 136, 760, 10.7326/0003-4819-136-10-200205210-00012 Williams, 2002, Is this patient clinically depressed?, JAMA, 287, 1160, 10.1001/jama.287.9.1160 Löwe, 2003, Predictors of psychiatric comorbidity in medical outpatients, Psychosom Med, 65, 764, 10.1097/01.PSY.0000079379.39918.17 Katon, 2004, Treatment of depression in primary care: where we are, where we can go, Med Care, 42, 1153, 10.1097/00005650-200412000-00001 Spitzer, 1999, Patient Health Questionnaire Primary Care Study Group: Validation and utility of a self-report version of PRIME-MD: The PHQ Primary-Care Study, JAMA, 282, 1737, 10.1001/jama.282.18.1737 Kroenke, 2001, The PHQ-9: validity of a brief depression severity measure, J Gen Intern Med, 16, 606, 10.1046/j.1525-1497.2001.016009606.x Diez-Quevedo, 2001, Validation and utility of the Patient Health Questionnaire in diagnosing mental disorders in 1,003 general-hospital Spanish inpatients, Psychosom Med, 63, 679, 10.1097/00006842-200107000-00021 Gräfe, 2004, Screening for psychiatric disorders with the Patient Health Questionnaire (PHQ): results from the German validation study, Diagnostica, 50, 171, 10.1026/0012-1924.50.4.171 Löwe, 2004, Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses, J Affect Disord, 78, 131, 10.1016/S0165-0327(02)00237-9 Löwe, 2004, Diagnosing ICD-10 depressive episodes: superior criterion validity of the Patient Health Questionnaire, Psychother Psychosom, 73, 386, 10.1159/000080393 Löwe, 2003, Detecting panic disorder in medical and psychosomatic outpatients: comparative validation of the Hospital Anxiety and Depression Scale, the Patient Health Questionnaire, a screening question, and physicians’ diagnosis, J Psychosom Res, 55, 515, 10.1016/S0022-3999(03)00072-2 Becker, 2002, Screening for somatization and depression in Saudi Arabia: a validation study of the PHQ in primary care, Int J Psychiatry Med, 32, 271, 10.2190/XTDD-8L18-P9E0-JYRV Lubetkin, 2003, Depression, anxiety, and associated health status in low-income Chinese patients, Am J Prev Med, 24, 354, 10.1016/S0749-3797(03)00017-5 Persoons, 2003, Anxiety and mood disorders in otorhinolaryngology outpatients presenting with dizziness: validation of the self-administered PRIME-MD patient health questionnaire and epidemiology, Gen Hosp Psychiatry, 25, 316, 10.1016/S0163-8343(03)00072-0 Löwe, 2004, Monitoring depression treatment outcomes with the Patient Health Questionnaire-9, Med Care, 42, 1194, 10.1097/00005650-200412000-00006 Zigmond, 1983, The Hospital Anxiety and Depression Scale, Acta Psychiatr Scand, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x World Health Organization Info Package: Mastering depression in primary care, Version 2.2. Copenhagen, Denmark, World Health Organization, Regional Office for Europe, 1998 First, 1995 2000 Löwe, 2004, Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9), J Affect Disord, 81, 61, 10.1016/S0165-0327(03)00198-8 Unützer, 2002, Collaborative care management of late-life depression in the primary-care setting: a randomized, controlled trial, JAMA, 288, 2836, 10.1001/jama.288.22.2836 Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 Glassman, 2002, Sertraline treatment of major depression in patients with acute MI or unstable angina, JAMA, 288, 701, 10.1001/jama.288.6.701 Kroenke, 2001, Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial, JAMA, 286, 2947, 10.1001/jama.286.23.2947 Kocsis, 2002, Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs. placebo, Arch Gen Psychiatry, 59, 723, 10.1001/archpsyc.59.8.723 Sheikh, 2004, Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness, J Am Geriatr Soc, 52, 86, 10.1111/j.1532-5415.2004.52015.x Lépine, 2004, A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder, Am J Psychiatry, 161, 836, 10.1176/appi.ajp.161.5.836 Bundesinstitut für Arzneimittel und Medizinprodukte: Recommendations for planning, performance, and evaluation of post-marketing surveillance studies, Nov. 12, 1998. http://www.bfarm.de/de/Arzneimittel/zul/bekanntm/index.php?more=awbver1.php:1998 Guy, 1976 Löwe, 2002 de Bruin, 1997, Assessing the responsiveness of a functional status measure: the Sickness Impact Profile versus the SIP-68, J Clin Epidemiol, 50, 529, 10.1016/S0895-4356(97)00047-4 Katz, 1992, Comparative measurement sensitivity of short and longer health status instruments, Med Care, 30, 917, 10.1097/00005650-199210000-00004 Wright, 1997, A comparison of different indices of responsiveness, J Clin Epidemiol, 50, 239, 10.1016/S0895-4356(96)00373-3 Koike, 2002, Improving the care for depression in patients with comorbid medical illness, Am J Psychiatry, 159, 1738, 10.1176/appi.ajp.159.10.1738 Spijker, 2004, Determinants of persistence of major depressive episodes in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS), J Affect Disord, 81, 231, 10.1016/j.jad.2003.08.005 Bagby, 2004, The Hamilton Depression Rating Scale: has the gold standard become a lead weight?, Am J Psychiatry, 161, 2163, 10.1176/appi.ajp.161.12.2163